{
    "clinical_study": {
        "@rank": "23544", 
        "acronym": "PET", 
        "arm_group": [
            {
                "arm_group_label": "Cohor 1 - 30 mg", 
                "arm_group_type": "Experimental", 
                "description": "Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562."
            }, 
            {
                "arm_group_label": "Cohort 2 ( adaptive dose, optional)", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1."
            }, 
            {
                "arm_group_label": "Cohort 3 ( adaptive dose, optional)", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1 and Cohort 2."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate D1 Receptor Occupancy (RO) following a single dose of PF-06412562\n      In healthy male volunteers"
        }, 
        "brief_title": "A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy Male Volunteers\n\n        Exclusion Criteria:\n\n        Evidence or history of clinically significant hepatic, renal, cardiovascular, endocrine,\n        hematologic, gastrointestinal, pulmonary, neurologic, oncologic, psychiatric, or allergic\n        disease Any condition possibly affecting drug absorption A positive urine drug screen"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02124213", 
            "org_study_id": "B7441005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohor 1 - 30 mg", 
                "description": "Subject will receive a single dose of 30 mg PF-06412562", 
                "intervention_name": "30 mg PF-06412562", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2 ( adaptive dose, optional)", 
                "description": "The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.", 
                "intervention_name": "PF-06412562", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3 ( adaptive dose, optional)", 
                "description": "The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.\nThis Cohort is optional.", 
                "intervention_name": "PF-06412562", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Receptor Occupancy", 
            "PET", 
            "D1 Receptor Agonist"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7441005&StudyName=A%20Study%20To%20Evaluate%20D1%20Receptor%20Occupancy%20%28RO%29%20Following%20Single%20Dose%20of%20PF-06412562%20In%20Healthy%20Male%20Volunteers"
        }, 
        "number_of_arms": "3", 
        "official_title": "Open Label Adaptive Design Study to Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562, Using Positron Emission Tomography (PET) With Ligand [11C]SCH23390 in Healthy Male Subjects", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Using Positron Emission Tomography and a radiotracer [11C]SCH23390, the PF-06142562 plasma exposure and RO in the striatum (average of caudate and putamen) will be measured in  healthy male subjects.", 
            "measure": "PF-06142562 plasma exposure and RO in the striatum", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02124213"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Area under the plasma concentration-time profile from time zero to the last plasma measurement at 4 hours (AUC0-4)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Average plasma concentration over 4 hours (Cav,0-4)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}